Yale University

A trial of integrated buprenorphine/naloxone and HIV clinical care.

TitleA trial of integrated buprenorphine/naloxone and HIV clinical care.
Publication TypeJournal Article
Year of Publication2006
AuthorsSullivan, Lynn E., Declan Barry, Brent A. Moore, Marek C. Chawarski, Jeanette M. Tetrault, Michael V. Pantalon, Patrick G. O'Connor, Richard S. Schottenfeld, and David A. Fiellin
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume43 Suppl 4
Date Published2006 Dec 15
KeywordsAdministration, Sublingual, Adult, Antiretroviral Therapy, Highly Active, Buprenorphine, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, HIV Infections, Humans, Male, Middle Aged, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Pilot Projects, Probability, Reference Values, Risk Factors, Treatment Outcome
AbstractUntreated opioid dependence adversely affects the care of human immunodeficiency virus (HIV)-positive patients. Buprenorphine, a partial opioid agonist, is available for maintenance treatment of opioid dependence in HIV specialty settings. We investigated the feasibility and efficacy of integrating buprenorphine, along with 2 levels of counseling, into HIV clinical care.
Alternate JournalClin. Infect. Dis.

External Links